We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tempest Therpeutics Inc | NASDAQ:TPST | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.30% | 3.37 | 3.35 | 3.41 | 3.43 | 3.27 | 3.35 | 244,257 | 00:39:58 |
Poster presentation details: | ||
Title: | PPAR-α Antagonist Enhances Immunotherapy and Anti | |
Angiogenic Therapy to Inhibit Murine Renal Cancer | ||
Abstract Number: | 3045 | |
Date & Time: | Monday, April 8, 2024; 1:30 – 5:00 p.m. PT | |
Session Title: | Oncogenic Transcription Factors | |
Location: | Poster Section 18 |
All regular abstracts are available for viewing via AACR’s online itinerary planner, located here.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor & Media Contacts
Sylvia WheelerWheelhouse Life Science Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@wheelhouselsa.com
i If approved by the FDA |
1 Year Tempest Therpeutics Chart |
1 Month Tempest Therpeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions